Paul L. Canner

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

Robert Altman, L Carreras, Rubén Sierra Díaz et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1994 · 3.3K citations

Thrombosis, Ischemic Stroke, Cardiovascular Disease +9

Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin

Paul L. Canner, Kenneth G. Berge, Nanette K. Wenger et al. · Journal of the American College of Cardiology · 1986 · 1.8K citations

Cardiovascular Disease, Health Policy, Long-term Benefit +9

The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial.

Florence H. Sheehan, Eugene Braunwald, Paul L. Canner et al. · Circulation · 1987 · 401 citations · Full text

Full Reperfusion, Coronary Artery Disease, Acute Myocardial Infarction +18

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)

Paul L. Canner, Curt D. Furberg, Michael L. Terrin et al. · The American Journal of Cardiology · 2005 · 226 citations

Healed Myocardial Infarction, Glycemic Status, Coronary Drug Project +7

The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project.

Robert C. Schlant, Sandra Forman, Jeremiah Stamler et al. · Circulation · 1982 · 179 citations

Epidemiology, Cardiovascular Epidemiology, Cardiovascular Disease +9